---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-23-017419"
form_type: "8-K"
ticker: "PRME"
cik: "0001894562"
company_name: "Prime Medicine, Inc."
filed_at: "2023-05-11T23:59:59+00:00"
generated_at: "2026-06-15T04:59:04.714376+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Prime Medicine reports Q1 net loss $39.4M, cash $263M; nominates first development candidate PM359 for CGD

## Summary
- Net loss of $39.4M for Q1 2023 vs $23.8M in Q1 2022; R&D expenses $30.9M.
- Cash, cash equivalents, investments and restricted cash $263.0M as of March 31, 2023; runway into 2025.
- Appointed Jeff Marrazzo (former CEO of Spark Therapeutics) to Board of Directors.
- U.S. PTO issued second patent (No. 11,643,652) and allowed third patent application for Prime Editing.
- Plans to initiate IND-enabling studies for PM359 in CGD in 2023; first IND filing as early as 2024.

## SEC filing metadata
- accession: 0001628280-23-017419
- form_type: 8-K
- ticker: PRME
- cik: 0001894562
- company_name: Prime Medicine, Inc.
- filed_at: 2023-05-11T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1894562/000162828023017419/0001628280-23-017419-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1894562/000162828023017419/prme-20230511.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-23-017419
- JSON: https://secwatch.observer/filing/0001628280-23-017419.json
- Plain text: https://secwatch.observer/filing/0001628280-23-017419.txt

## Key facts
- Earnings Releases
  Prime Medicine, Inc. reported financial results for first quarter ended March 31, 2023.
  - Period: first quarter ended March 31, 2023
  - Result: reported results
  source text: Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today reported financial results and provided business updates for the first quarter ended March 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1894562/000162828023017419/0001628280-23-017419-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.